Novartis and BenevolentAI sign AI oncology deal

Novartis and BenevolentAI sign AI oncology deal

Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments. BenevolentAI, a UK-headquartered artificial intelligence (AI) company, announced the collaboration agreement on Friday, September 6. Novartis’ precision medicine team (which sits within the company’s global drug development unit) […] Click here to view original web page at[…]

Major gaps exist in patient understanding of genomic test results, Lung-MAP study shows

Major gaps exist in patient understanding of genomic test results, Lung-MAP study shows

Cancer cell during cell division. Credit: National Institutes of Health A majority of cancer patients don’t understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP) . In a […] Click here to view original[…]

Tempus, Genmab Enter Oncology Biomarker Collaboration

Tempus, Genmab Enter Oncology Biomarker Collaboration

Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that will leverage Tempus’ sequencing capabilities and platform of integrated clinical and molecular data with Genmab’s translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, […] Click here to view original[…]